Full Press Release Details
January 11-14, 2021 2021 J.P. Morgan 39th Annual Healthcare Conference 1Exhibit 99.1 INNOVATING TREATMENTS THROUGH ADVANCED PLACENTAL SCIENCE January 11-14, 2021 2021 J.P. Morgan 39th Annual Healthcare Conference 1
IMPORTANT CAUTIONARY STATEMENT This presentation contains
forward-looking statements. Investors are cautioned against placing undue reliance on these statements. All statements relating to events or results that may occur in the future are forward-looking statements, including, without limitation,
statements regarding the following: the regulatory pathway for our products, including our existing and planned investigative new drug application and pre-market approval requirements, the timing, design and success of our clinical trials
and pursuit of biologic license applications ("BLAs") and other regulatory approvals for certain products; the process of obtaining regulatory clearances or approvals to market a biological product or medical device from the FDA or
similar regulatory authorities outside of the U.S. is costly and time consuming, and such clearances or approvals may not be granted on a timely basis, or at all. our expectations regarding our ability to continue marketing our micronized
products and certain other products during and following the end of the period of enforcement discretion announced by the United States Food and Drug Administration ("FDA"); to the extent our products do not qualify for regulation as
human cells, tissues and cellular and tissue-based products solely under Section 361 of the Public Health Service Act ("Section 361"), this could result in removal of the applicable products from the market, would make the introduction
of new tissue products more expensive and would significantly delay the expansion of our tissue product offerings and subject us to additional post-market regulatory requirements. our expectations regarding future revenue growth, including
product innovations, expansion into additional domestic and international markets, our product pipeline and the potential to increase our product offerings, and future research and development expenses; future revenue growth will require continued
or additional market, regulatory, and payor acceptance of our products. ongoing and future effects arising from the COVID-19 pandemic and the Company's plans to adhere to governmental recommendations with respect thereto; the COVID-19
pandemic and governmental and societal responses thereto have adversely affected our business, results of operations and financial condition, and the continuation of the pandemic or the outbreak of other health epidemics could harm our business,
results of operations, and financial condition. our expectations regarding market opportunities, expected growth in certain markets, and demographic and market trends; there can be no assurance that the demand for our products will grow.
our expectations regarding future staffing levels and future levels of cash, nets sales, gross margin, investments, and expenses; future operating results and financial conditions are subject to numerous risks and uncertainties; and
our expectations regarding our ability to resolve certain legal matters; We are currently, and may in the future be, subject to substantial litigation and ongoing investigations that could cause us to incur significant legal expenses and result in
harm to our business and we can provide no assurance that we will resolve such matters on terms that are reasonable or that existing resources will be adequate to resolve such matters. 2IMPORTANT CAUTIONARY STATEMENT This presentation contains
forward-looking statements. Investors are cautioned against placing undue reliance on these statements. All statements relating to events or results that may occur in the future are forward-looking statements, including, without limitation,
statements regarding the following: the regulatory pathway for our products, including our existing and planned investigative new drug application and pre-market approval requirements, the timing, design and success of our clinical trials
and pursuit of biologic license applications ("BLAs") and other regulatory approvals for certain products; the process of obtaining regulatory clearances or approvals to market a biological product or medical device from the FDA or
similar regulatory authorities outside of the U.S. is costly and time consuming, and such clearances or approvals may not be granted on a timely basis, or at all. our expectations regarding our ability to continue marketing our micronized
products and certain other products during and following the end of the period of enforcement discretion announced by the United States Food and Drug Administration ("FDA"); to the extent our products do not qualify for regulation as
human cells, tissues and cellular and tissue-based products solely under Section 361 of the Public Health Service Act ("Section 361"), this could result in removal of the applicable products from the market, would make the introduction
of new tissue products more expensive and would significantly delay the expansion of our tissue product offerings and subject us to additional post-market regulatory requirements. our expectations regarding future revenue growth, including
product innovations, expansion into additional domestic and international markets, our product pipeline and the potential to increase our product offerings, and future research and development expenses; future revenue growth will require continued
or additional market, regulatory, and payor acceptance of our products. ongoing and future effects arising from the COVID-19 pandemic and the Company's plans to adhere to governmental recommendations with respect thereto; the COVID-19
pandemic and governmental and societal responses thereto have adversely affected our business, results of operations and financial condition, and the continuation of the pandemic or the outbreak of other health epidemics could harm our business,
results of operations, and financial condition. our expectations regarding market opportunities, expected growth in certain markets, and demographic and market trends; there can be no assurance that the demand for our products will grow.
our expectations regarding future staffing levels and future levels of cash, nets sales, gross margin, investments, and expenses; future operating results and financial conditions are subject to numerous risks and uncertainties; and
our expectations regarding our ability to resolve certain legal matters; We are currently, and may in the future be, subject to substantial litigation and ongoing investigations that could cause us to incur significant legal expenses and result in
harm to our business and we can provide no assurance that we will resolve such matters on terms that are reasonable or that existing resources will be adequate to resolve such matters. 2
IMPORTANT CAUTIONARY STATEMENT (CONT.) Forward-looking statements
generally can be identified by words such as "expect," "will," "change," "intend," "seek," "target," "future," "plan," "continue,"
"potential," "possible," "could," "estimate," "may," "anticipate," "to be" and similar expressions. These statements are based on numerous assumptions and involve
known and unknown risks, uncertainties and other factors that could significantly affect the Company's operations and may cause the Company's actual actions, results, financial condition, performance or achievements to differ materially.
Factors that may cause such a difference include, without limitation, those discussed under the heading "Risk Factors" in our most recent Form 10-Q and in our Form 10-K for the year ended December 31, 2019. Unless required by law, the
Company does not intend, and undertakes no obligation, to update or publicly release any revision to any forward-looking statements, whether as the result of new information, the occurrence of subsequent events, a change in circumstances or
otherwise. Each forward-looking statement contained herein is specifically qualified in its entirety by the aforementioned factors. 3IMPORTANT CAUTIONARY STATEMENT (CONT.) Forward-looking statements generally can be identified by words such as
"expect," "will," "change," "intend," "seek," "target," "future," "plan," "continue," "potential," "possible,"
"could," "estimate," "may," "anticipate," "to be" and similar expressions. These statements are based on numerous assumptions and involve known and unknown risks, uncertainties and other
factors that could significantly affect the Company's operations and may cause the Company's actual actions, results, financial condition, performance or achievements to differ materially. Factors that may cause such a difference
include, without limitation, those discussed under the heading "Risk Factors" in our most recent Form 10-Q and in our Form 10-K for the year ended December 31, 2019. Unless required by law, the Company does not intend, and undertakes no
obligation, to update or publicly release any revision to any forward-looking statements, whether as the result of new information, the occurrence of subsequent events, a change in circumstances or otherwise. Each forward-looking statement contained
herein is specifically qualified in its entirety by the aforementioned factors. 3
LEADING PRODUCT PORTFOLIO POSITIONED FOR GROWTH $1.1B 84% $256M 3 2 1
Market Cap Gross Margin TTM Net Sales 265+ 2,000,000+ 725+ 4 5 Field Sales Allografts Distributed Employees 5 Personnel Reimbursement 30M (U.S.) $6.2-$18.7B coverage, U.S.: 6 8 with diabetes Medicare cost of DFU/yr 5-year shelf life 300M+
Room temp storage 2.9M $60K/yr lives 300+ regulatory proteins 7 9 chronic wounds Cost of amputation care 2 1,000+ patients 10,000+ ft 2M+ 17.5M+ studied under IND U.S. patients treated of ISO Class 7 10 U.S. KOA patients 12 clinical
programs 11 clean room space for PF annually (1) Trailing twelve months period ended September 30, 2020, as reported in applicable SEC filings. (2) Represents GAAP gross margin for the trailing twelve months period ended September 30, 2020. (3)
Based on closing stock price on January 7, 2021 (4) As of January 8, 2021; (5) As of December 31, 2020; (6) Sen CK. Human Wounds and Its Burden: An Updated Compendium of Estimates. Adv Wound Care (New Rochelle). 2019;8(2):39-48.
doi:10.1089/wound.2019.0946; (7) BioMed GPS SmartTrak; (8) Nussbaum SR, Carter MJ, Fife CE, DaVanzo J, Haught R, Nusgart M, et al. An economic evaluation of the impact, cost, and medicare policy implications of chronic nonhealing wounds. Value
Health. 2018;21(1):27-32; (9) D. G. Armstrong, M. A. Swerdlow, A. A. Armstrong, M. S. Conte, W. V. Padula, and S. A. Bus, "Five year mortality and direct costs of care for people with diabetic foot complications 4 are comparable to
cancer," Journal of Foot and Ankle Research, vol. 13, no. 1. BioMed Central Ltd., Mar. 24, 2020, doi: 10.1186/s13047-020-00383-2. (10) Global Data Knee Reconstruction Data Model United States 2020 (11) Tong KB, Furia J. Economic burden of
plantar fasciitis treatment in the United States. Am J Orthop (Belle Mead NJ). 2010;39(5):227-231; (12) MiMedx IND Clinical Trial Programs; Plantar Fasciitis Phase 2B: 147; Plantar Fasciitis Phase 3: 276; Knee Osteoarthritis Phase 2B: 430+; Achilles
Tendonitis Phase 3: 158. LEADING PRODUCT PORTFOLIO POSITIONED FOR GROWTH $1.1B 84% $256M 3 2 1 Market Cap Gross Margin TTM Net Sales 265+ 2,000,000+ 725+ 4 5 Field Sales Allografts Distributed Employees 5 Personnel Reimbursement 30M (U.S.)
$6.2-$18.7B coverage, U.S.: 6 8 with diabetes Medicare cost of DFU/yr 5-year shelf life 300M+ Room temp storage 2.9M $60K/yr lives 300+ regulatory proteins 7 9 chronic wounds Cost of amputation care 2 1,000+ patients 10,000+
ft 2M+ 17.5M+ studied under IND U.S. patients treated of ISO Class 7 10 U.S. KOA patients 12 clinical programs 11 clean room space for PF annually (1) Trailing twelve months period ended September 30, 2020, as reported in applicable SEC filings. (2)
Represents GAAP gross margin for the trailing twelve months period ended September 30, 2020. (3) Based on closing stock price on January 7, 2021 (4) As of January 8, 2021; (5) As of December 31, 2020; (6) Sen CK. Human Wounds and Its Burden: An
Updated Compendium of Estimates. Adv Wound Care (New Rochelle). 2019;8(2):39-48. doi:10.1089/wound.2019.0946; (7) BioMed GPS SmartTrak; (8) Nussbaum SR, Carter MJ, Fife CE, DaVanzo J, Haught R, Nusgart M, et al. An economic evaluation of the impact,
cost, and medicare policy implications of chronic nonhealing wounds. Value Health. 2018;21(1):27-32; (9) D. G. Armstrong, M. A. Swerdlow, A. A. Armstrong, M. S. Conte, W. V. Padula, and S. A. Bus, "Five year mortality and direct costs of
care for people with diabetic foot complications 4 are comparable to cancer," Journal of Foot and Ankle Research, vol. 13, no. 1. BioMed Central Ltd., Mar. 24, 2020, doi: 10.1186/s13047-020-00383-2. (10) Global Data Knee Reconstruction Data
Model United States 2020 (11) Tong KB, Furia J. Economic burden of plantar fasciitis treatment in the United States. Am J Orthop (Belle Mead NJ). 2010;39(5):227-231; (12) MiMedx IND Clinical Trial Programs; Plantar Fasciitis Phase 2B: 147; Plantar
Fasciitis Phase 3: 276; Knee Osteoarthritis Phase 2B: 430+; Achilles Tendonitis Phase 3: 158.
FROM TRANSFORMATION TO INVESTMENT Positioning for pipeline Investing
acceleration in core business for growth Focusing capital on strategic initiatives 5FROM TRANSFORMATION TO INVESTMENT Positioning for pipeline Investing acceleration in core business for growth Focusing capital on strategic initiatives 5
MIMEDX IS A PIONEER IN PLACENTAL BIOLOGICS Promising Late- Core Business
Stage Pipeline Distinct drivers of significant shareholder value with current and future growth potential 6MIMEDX IS A PIONEER IN PLACENTAL BIOLOGICS Promising Late- Core Business Stage Pipeline Distinct drivers of significant shareholder value with
current and future growth potential 6
DIFFERENTIATED PLATFORM POSITIONED TO EXCEED MARKET GROWTH All amniotic
products are not the same Shelf-stable with 5-year shelf life Human-derived, immunologically privileged & terminally sterilized Full vertical integration with scalable donation & recovery network
Peer-reviewed, published data recognized by AHRQ Broad reimbursement coverage Strong intellectual property protection +10% TARGET GROWTH +8-10% CAGR Source: BioMed GPS SmartTrak; CAGR 2019-2024E; AHRQ = Agency for Healthcare Research
and Quality 7DIFFERENTIATED PLATFORM POSITIONED TO EXCEED MARKET GROWTH All amniotic products are not the same Shelf-stable with 5-year shelf life Human-derived, immunologically privileged & terminally sterilized Full
vertical integration with scalable donation & recovery network Peer-reviewed, published data recognized by AHRQ Broad reimbursement coverage Strong intellectual property protection +10% TARGET GROWTH +8-10% CAGR Source:
BioMed GPS SmartTrak; CAGR 2019-2024E; AHRQ = Agency for Healthcare Research and Quality 7
INVESTMENTS IN CGMP MANUFACTURING ENHANCE COMPETITIVE ADVANTAGES
Rigorous regulatory standards from tissue donation to final product benefit entire portfolio and ensure consistency and controls throughout manufacturing process Final Release Shelf-Stable Testing, including Packaged Purity, Potency Product and
Identity 1 2 3 4 5 Delivery of Donated Placental Proprietary Terminal Shelf-Stable Healthy Baby Tissues Recovered Processing Sterilization to Final Release Packaged via Caesarean and Tested with ISO Standards Testing Product Section CGMP Systems and
Quality Release Controls CGMP = Current Good Manufacturing Practice 8INVESTMENTS IN CGMP MANUFACTURING ENHANCE COMPETITIVE ADVANTAGES Rigorous regulatory standards from tissue donation to final product benefit entire portfolio and ensure consistency
and controls throughout manufacturing process Final Release Shelf-Stable Testing, including Packaged Purity, Potency Product and Identity 1 2 3 4 5 Delivery of Donated Placental Proprietary Terminal Shelf-Stable Healthy Baby Tissues Recovered
Processing Sterilization to Final Release Packaged via Caesarean and Tested with ISO Standards Testing Product Section CGMP Systems and Quality Release Controls CGMP = Current Good Manufacturing Practice 8
ROBUST COMMERCIAL INFRASTRUCTURE DIFFERENTIATES FIELD SALES FORCE Q3
2020 Revenue (TTM) In-patient 29% Private Reimbursement Office coverage, U.S. 29% Out-patient 300M+ lives 30% Other 12% 265+ field sales personnel supported by an Product attributes are easily integrated into expanding Medical
Science Liaison team to multiple sites of care to ensure broad patient educate customers access Robust clinical evidence to differentiate Field-based reimbursement & national account within the category and stabilize teams
aligned to field sales personnel to accelerate reimbursement shifts commercial execution Current multi-year contracts in place with Patient Insurance Verification Team for intake and the largest GPOs and IDNs processing of insurance
to determine coverage GPO = Group Purchasing Organization; IDN = Integrated Delivery Network 9ROBUST COMMERCIAL INFRASTRUCTURE DIFFERENTIATES FIELD SALES FORCE Q3 2020 Revenue (TTM) In-patient 29% Private Reimbursement Office coverage, U.S. 29%
Out-patient 300M+ lives 30% Other 12% 265+ field sales personnel supported by an Product attributes are easily integrated into expanding Medical Science Liaison team to multiple sites of care to ensure broad patient educate customers
access Robust clinical evidence to differentiate Field-based reimbursement & national account within the category and stabilize teams aligned to field sales personnel to accelerate reimbursement shifts commercial execution
Current multi-year contracts in place with Patient Insurance Verification Team for intake and the largest GPOs and IDNs processing of insurance to determine coverage GPO = Group Purchasing Organization; IDN = Integrated Delivery
NEAR-TERM INVESTMENTS PRIORITIZE 10%+ FIELD SALES TEAM EXPANSION Core
Business Increase Market Capture Invest to Enhance Opportunity Disproportionate Commercial Share Excellence Model 2 3 1 10NEAR-TERM INVESTMENTS PRIORITIZE 10%+ FIELD SALES TEAM EXPANSION Core Business Increase Market Capture Invest to Enhance
Opportunity Disproportionate Commercial Share Excellence Model 2 3 1 10
TARGETED INVESTMENT FOR Current primary market GEOGRAPHIC EXPANSION 1-2
year expansion 2-3 year expansion JAPAN UK GERMANY Total Wound Care Market ~$430M ~$380M ~$740M DFU + VLU (patients) 650K 225K 500K MiMedx Addressable Market (patients) 100K 35K 80K Anticipated Approval Status Approved Approved mid-2021 3-6 months
Reimbursement Status In process In process post-approval Source: Global Data Tissue Engineered-Skin Sub Data Model Wound Management Japan, Germany and UK Year 2020 - retrieved Sept 2020; Management estimates; MiMedx Addressable Market
represents assumed, eventual 15% penetration of the addressable market. Reaching this level is subject to numerous risks 11 and uncertainties, including regulatory and market acceptance, and appropriate reimbursement. Investors are cautioned that
actual results may differ materially.TARGETED INVESTMENT FOR Current primary market GEOGRAPHIC EXPANSION 1-2 year expansion 2-3 year expansion JAPAN UK GERMANY Total Wound Care Market ~$430M ~$380M ~$740M DFU + VLU (patients) 650K 225K 500K MiMedx
Addressable Market (patients) 100K 35K 80K Anticipated Approval Status Approved Approved mid-2021 3-6 months Reimbursement Status In process In process post-approval Source: Global Data Tissue Engineered-Skin Sub Data Model Wound Management Japan,
Germany and UK Year 2020 - retrieved Sept 2020; Management estimates; MiMedx Addressable Market represents assumed, eventual 15% penetration of the addressable market. Reaching this level is subject to numerous risks 11 and uncertainties,
including regulatory and market acceptance, and appropriate reimbursement. Investors are cautioned that actual results may differ materially.
2021 INVESTMENTS REPRESENT SIGNIFICANT INCREASE IN R&D TO SUPPORT
CORE MARKET AND PIPELINE GROWTH OBJECTIVES Core Business Pipeline PROTECT GROW CORE PRODUCT ADVANCE EXISTING AREAS BUSINESS INNOVATION TIMELINE TO BLA OF USE BLA = Biologics License Application 122021 INVESTMENTS REPRESENT SIGNIFICANT INCREASE IN
R&D TO SUPPORT CORE MARKET AND PIPELINE GROWTH OBJECTIVES Core Business Pipeline PROTECT GROW CORE PRODUCT ADVANCE EXISTING AREAS BUSINESS INNOVATION TIMELINE TO BLA OF USE BLA = Biologics License Application 12